Johnson & Johnson (JNJ)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Johnson & Johnson (JNJ)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH659D
  • |
  • Pages: 516
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Johnson & Johnson (J&J) engages in the research and development, manufacture and sale of a range of healthcare products. Its primary focus is on the development of products related to human health and well-being. The company provides pharmaceuticals in immunology, cancer, neuroscience, infectious, cardiovascular and metabolic diseases areas; consumer products in baby care, oral care, beauty, over-the-counter (OTC) pharmaceutical, women's health and wound care categories; and medical devices for use in the cardiovascular, orthopedic, surgery, diabetes care and vision care fields. J&J distributes pharmaceutical and medical products to retailers, wholesalers, health care professionals and hospitals; and consumer products through retail outlets and distributors. The company provides its products in the US; Europe; Asia-Pacific and Africa; and Western Hemisphere (excluding the US). J&J is headquartered in New Brunswick, New Jersey, the US.

Johnson & Johnson (JNJ)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 12

List of Figures 20

Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 21

Johnson & Johnson, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 22

Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 23

Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 24

Johnson & Johnson, Medical Devices Deals, 2011 to YTD 2017 26

Johnson & Johnson, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 28

Johnson & Johnson, Pharmaceuticals & Healthcare, Deal Details 59

Asset Purchase 59

Cilag Acquires Rights to Rhinocort Aqua Outside the US from Astrazeneca 59

Janssen Pharma Acquires Royalty Rights To Incivo From Vertex Pharma For US$152 Million 59

Janssen Pharma Acquires Investigational NS5A Inhibitor From Medivir 61

J.B. Chemicals Completes Sale Of Its Russian OTC Business To Cilag 62

Venture Financing 63

Pulmocide Raises USD30.4 Million in Series B Financing 63

Grail Raises Funds in First Tranche of Series B Financing 64

Fusion Pharma Raises USD19 Million in Series A Financing 67

SuperX Raises USD11 Million in Series A Financing 67

Caelus Health Raises USD2.7 Million in Series A Financing 68

ApoGen Biotech Raises USD7 Million in Series A Financing 69

ReVision Optics Raises USD32 Million in Venture Financing 70

Blackthorn Therapeutics Raises USD40 Million in Series A Financing 72

V-Wave Raises USD28 Million in Venture Financing 73

Lodo Therapeutics Raises USD17 Million in Series A Financing 74

Aelix Therapeutics Raises USD12.7 Million in Series A Financing 75

Petra Pharma Raises USD48 Million in Series A Financing 76

Navitor Pharma Raises USD33 Million in Series B Financing 78

First Aid Shot Therapy Raises USD24 Million in Series C Financing 79

PrEP Biopharm Raises USD32.4 Million in Series A Financing Round 80

Asceneuron Raises USD30.6 Million in Series A Financing 81

Merus Raises USD46.4 Million in First Tranche of Series C Financing 83

Alligator Bioscience to Raise Funds through Venture Financing 84

Protagonist Therapeutics Raises USD40 Million in Series C Financing 85

PhaseBio Pharma Raises USD40 Million in Series C Venture Financing 86

Protagonist Therapeutics Raises Additional Funds through Second Tranche of Series B Venture Financing 88

La Lumiere Raises USD20 Million in Series B Venture Financing 89

Tetra Discovery Raises Funds through Venture Financing 90

XW Labs Raises USD5.5 Million in Series A Financing 90

Inivata Raises USD6.5 Million in Venture Financing 91

Inviata Raises USD6.5 Million in Venture Financing 92

ViaCyte Raises Additional USD5.4 Million in Series C-1 Venture Financing 93

Ascelegen Therapeutics Raises Funds through Venture Financing 94

Padlock Therapeutics Raises Funds through Series A Financing 95

Navitor Pharma Raises USD24 Million in Series A Financing 96

Aduro BioTech Raises USD55 Million in Series C Financing 97

Rodin Therapeutics Raises USD13 Million in Series A Venture Financing 98

Assembly Pharma Raises Funds Through Seed Financing 99

Alios BioPharma Raises US$41 Million In Series B Venture Financing 100

Covagen Raises US$50.3 Million In Series B Financing 101

Novira Therapeutics Raises US$28 Million In Series A Financing 103

SutroVax Raises Funds Through Initial Financing Round 104

TopiVert Raises USD28 Million in Venture Financing 105

TopiVert Raises US$7.4 Million In Venture Financing 106

Pulmocide Raises US$27.4 Million In Series A Financing 108

Biocartis Raises US$40.5 Million In Series E Financing 109

Merus Raises US$42 Million In Extended Series B Financing 111

Rodin Therapeutics Raises Funds Through Seed Financing 113

Vedanta Biosciences Raises Funds Through Venture Financing 113

XO1 Raises USD11 Million in Venture Financing 114

X01 Raises US$11 Million In Series A Financing 115

Catalyst Biosciences Secures USD5.07 Million in Venture Funding 116

Novira Therapeutics Secures USD25 Million in Venture Funding 117

Aquinox Pharma Raises US$18 Million In Series C Financing 118

Biocartis Raises US$44.7 Million In Series D Financing 119

Genocea Biosciences Raises US$30 Million In Series C Financing 120

Aragon Pharma Raises US$50 Million In Series D Financing 123

PhaseBio Pharma Raises Additional US$23 Million In The Third Tranche Of Series B Financing Round 124

Celladon Raises Additional US$10 Million In Series D Financing 125

Direct Flow Medical Secures USD0.28 Million in Venture Funding 127

Coherex Medical Secures USD16.5 Million in Venture Funding 128

Aragon Pharma Raises US$42 Million In Series C Financing 128

Biocartis Secures US$96 Million In Series C Financing Round 130

Novira Therapeutics Secures US$1 Million In Second Round Of Seed Financing 131

Spinal Modulation Secures US$30 Million In Series D Financing 132

23andMe Raises Additional USD9 Million in Series C Financing 134

Genocea Biosciences Secures US$35 Million In Series B Venture Financing 135

Private Equity 137

Johnson & Johnson Innovation-JJDC Invests USD4.7 Million in TRACON Pharma 137

Water Street Healthcare Partners Acquires OraPharma 138

Partnerships 139

Janssen Amends Licensing Agreement with Gilead for STR 139

Janssen Enters Into Licensing Agreement With PATH For Rilpivirine 140

Phagelux Enters into Agreement with Johnson & Johnson Consumer 141

Janssen Research & Development Enters into Agreement with Castleman Disease Collaborative Network 141

PeptiDream Enters into Agreement with Janssen Pharma 142

Janssen Pharma Enters into Partnership with Premier 143

Renova Therapeutics Enters into Agreement with Janssen Pharma 144

Mitsubishi Tanabe Pharma Enters into Co-Promotion Agreement with Janssen Pharma for Stelara 144

Janssen Research & Development Enters into Research Agreement with Weizmann Institute of Science 145

Janssen Research & Development Enters into Agreement with DayTwo and the Weizmann Institute of Science 146

Janssen Research & Development Enters into Agreement with ChemDiv 147

DePuy Synthes Enters into Co-Promotional Agreement with Pacira Pharma for EXPAREL 148

Janssen Vaccines & Prevention Enters into Research and Licensing Option Agreement with Synthetic Genomics 149

Janssen Biotech Partners with Weill Cornell Medicine to Develop Prostate Cancer Therapies 150

Janssen Pharma Enters into Partnership with Bird Rock Bio 150

Amorsa Therapeutics Enters into Partnership with Janssen Pharmaceuticals 151

Janssen Pharma and Medicines for Malaria Venture to Develop Injectable Anti-Malarial Agents 151

Karolinska Institutet Partners with Johnson & Johnson Companies 152

Janssen Biotech Enters into Partnership with Bristol-Myers 153

Janssen Biotech Enters into Clinical Trial Agreement with Onyx Pharma 154

HitGen Enters into Agreement with Janssen Biotech 154

Innovative Targeting Solutions Enters into Research Agreement with Janssen Biotech 155

Xycrobe Therapeutics Enters into Research Agreement with Johnson & Johnson Consumer 156

Philogen Enters into Co-Development Agreement with Janssen Biotech 156

Diamyd Medical Enter into Partnership with Janssen R&D, JDRF and UAB 157

Bristol-Myers Squibb Enters into Research Agreement with Janssen Biotech 158

Amyris Enters into Research Agreement with Janssen Biotech 159

Janssen Research & Development Enters into Agreement with Genentech 160

Mitsubishi Tanabe Pharma Enters into Distribution Agreement with Janssen Biotech 161

DiamiR Enters into Research Agreement with Janssen Pharma 161

Janssen Biotech Enters into Research Agreement with David H. Koch Institute for Integrative Cancer 162

Janssen Biotech Enters into Agreement with HUB foundation 163

Janssen Pharma Enters into Agreement with University of Pennsylvania 163

Janssen Pharma Enters into Agreement with University of Wisconsin-Madison 164

Johnson & Johnson Consumer Enters into Agreement with ProdermIQ 165

Johnson & Johnson Consumer Enters into Research Agreement with University of Pennsylvania 165

Janssen Biotech Enters into Research Agreement with David H. Koch Institute for Integrative Cancer 166

ViiV Healthcare Enters into Agreement with Janssen Sciences Ireland UC 167

Janssen Pharma Enters into Agreement with University of California, San Diego 167

Enterome Bioscience Enters into Research Agreement with Janssen Biotech 168

Johnson & Johnson Consumer Enters into Agreement with BioMed X 169

Janssen Pharma Enters into Research Agreement with Institute for Systems Biology 169

Janssen Research & Development Enters into Research Agreement with Skaggs School of Pharmacy and Pharmaceutical Sciences 170

Janssen Biotech Enters into Agreement with Eureka Therapeutics 171

Intrexon Enters into Research Agreement with Janssen Pharma 171

Cypralis Enters into Research Agreement with Janssen Pharma 172

Janssen Pharma Enters into Agreement with Foundation for Innovative New Diagnostics 173

Bioaster, Cancer Research Center of Lyon and Janssen-Cilag Enter into Agreement 174

Nuevolution Enters into Discovery Agreement with Janssen Biotech 174

enGene Enters into Agreement with Janssen Biotech 175

OICR and Novera Therapeutics Enter into Co-Development Agreement with Janssen Biotech 176

BlinkBio Enters into Discovery Agreement with Janssen Pharma 177

UbiVac Enters into Agreement with Janssen Biotech 177

Protectimmun Enters into Research Agreement with Janssen Biotech And Imperial College 178

Nextera Enters into Research Agreement with Janssen Biotech 179

Johnson & Johnson Innovation Enters into Research Agreement with Washington University 180

Janssen Biotech Enters into Research Agreement with Emulate 180

Johnson & Johnson Innovation Partners with Lead Discovery Center 181

Johnson & Johnson Enters into Agreement with University of the Witwatersrand 182

Janssen Cilag Enters into Agreement with UniQuest 182

AC Immune Enters into Research Agreement with Janssen Pharma 183

X-Chem Expands Agreement with Janssen Biotech 184

Vectura Enters into Development and License Agreement with Janssen Biotech 184

Isis Pharma Enters into Agreement with Janssen Biotech to Discover and Develop RNA-Targeted Therapeutics 185

Sevion Therapeutics Enters into Discovery Agreement with CNA Development 186

Atreca Enters into Research Agreement with Janssen Biotech 187

Vaccinex Enters into Research Agreement with Janssen Research & Development 188

Mitsubishi Tanabe Enters into Co-Promotion Agreement with Johnson & Johnson K.K. 188

Weill Cornell Medical College Enters into Co-Development Agreement with Janssen Biotech and Johnson & Johnson Innovation 189

Johnson & Johnson Enters into Co-Development Agreement with University of Manchester 190

ViiV Healthcare Enters into Co-Development Agreement with Janssen R&D Ireland 191

Alector Enters Into Research Agreement With Janssen Pharma 192

Jubilant Biosys Extends Drug Discovery Agreement With Janssen Pharma 192

University of Texas MD Anderson Cancer Center Enters Into Co-Development Agreement With Johnson & Johnson Innovation And Janssen Biotech 193

Nodality Enters Into Research Agreement With Johnson & Johnson Innovation 195

Scholar Rock Enters Into Research Collaboration With Johnson & Johnson Innovation And Janssen Biotech 195

Intrexon Enters Into R&D Agreement With Johnson & Johnson Innovation For Skin And Hair Products 197

Capricor Enters Into Co-Development Agreement With Janssen For Cell Therapy For Cardiovascular Applications 197

Evotec Enters Into Co-Development Agreement With Johnson & Johnson 198

AstraZeneca Enters Into Co-Promotion Agreement With Janssen For Abiraterone Acetate 199

Joslin Diabetes Center Enters Into R&D Agreement With Johnson & Johnson For Diabetes Management 200

Open Monoclonal Expands Agreement with CNA Development 201

DCPrime And Janssen Pharma Enter Into Research Agreement For Cell-Based Vaccine 202

Katholieke Universiteit Leuven And Wellcome Trust Enter Into Agreement With Janssen Pharma To Develop Dengue Antiviral Drugs 202

ex scientia Enters into Agreement with Janssen Research & Development 204

Mellitech Enters into Agreement with Janssen Pharma 204

Second Genome Enters Into Agreement With Janssen Biotech For Microbiome Drug Discovery 205

Janssen Biotech Enters Into Agreement With CRT And ICR To Discover Multiple Myeloma Drug 206

Araxes Pharma Enters Into Drug Discovery Agreement With Janssen Biotech For Cancer 207

Idenix Pharma Enters Into Co-Development Agreement With Janssen Pharma 208

Open Monoclonal Technology Enters Into Agreement With CNA Development For OmniRat Antibody 209

Beactica Enters Into Research Agreement With Janssen Research & Development 209

Janssen-Cilag Enters Into Research Agreement With University of Melbourne 210

Takeda Pharma Enters Into Distribution Agreement With Johnson & Johnson For Seven OTC Brands 211

Artes Biotechnology Enters Into Co-Development Agreement With Crucell 212

Selventa Enters Into Co-Development Agreement With Janssen Research & Development 212

Johnson & Johnson Enters Into Co-Development Agreement With University of Queensland 213

Dendright Enters Into Research Agreement With Janssen-Cilag 214

FORMA Therapeutics Enters Into Co-Development Agreement With Janssen Biotech 215

ChemDiv Enters Into Research Agreement With Janssen Pharmaceutica And Tibotec Pharma 216

Molecular Partners Enters Into Research Agreement With Janssen Biotech 216

Topivert Enters into Drug Discovery Collaboration Agreement with RespiVert 217

Skyline Diagnostics Enters Into Research Collaboration With Johnson & Johnson Pharma 218

Jubilant Enters Into Drug Discovery Agreement With Janssen Pharmaceutica 219

ChemRar High Tech Center Enters Into Co-Development Agreement With Janssen Pharma 220

Synthes Enters Into Co-Development Agreement With Eli Lilly 220

PATH Malaria Vaccine Initiative Enters Into An Agreement With Crucell And GlaxoSmithKline 221

NeuroSearch Extends Research Agreement With Janssen Pharmaceutica 223

Beactica Enters Into An Agreement With Janssen 223

Merck Amends Distribution Agreement With Johnson & Johnson 224

Medivir Enters Into Collaboration With Janssen Pharmaceutica 225

Johns Hopkins Brain Science Institute Enters Into An Agreement With Ortho-McNeil-Janssen 226

Sanford-Burnham Medical Enters Into Collaboration With Ortho-McNeil-Janssen Pharma 227

Veridex Enters Into Co-Development Agreement With Massachusetts General Hospital 228

Stereotaxis Amends Co-Development Agreement With Biosense Webster 229

Licensing Agreements 230

Janssen Pharma Enters into Licensing Agreement with Medivir 230

Janssen Biotech Enters into Licensing Agreement with Trianni 231

Janssen Biotech Enters into Licensing Agreement with Ablexis 232

Akebia Therapeutics Enters into Licensing Agreement with Janssen Pharma 232

Janssen Pharma Enters into Licensing Agreement with University of Massachusetts 233

CPDC Enters into Licensing Agreement with Janssen Biotech for Centyrin 234

OCTIMET Oncology Enters into Licensing Agreement with Janssen Pharma 235

Janssen Expands Licensing Agreement with Gilead 235

BenevolentAI Enters into Licensing Agreement with Janssen Pharma 237

TRACON Pharma Enters into Licensing Agreement with Janssen Pharma for TRC253 237

TRACON Pharma Enters into Licensing Agreement with Janssen Pharma for TRC694 238

Geron Enters into License Agreement with Janssen Pharma for Synthesis of Monomers 240

Geron Enters into Licensing Agreement with Janssen Pharmaceuticals for RNA Interference 240

GlaxoSmithKline Enters into Licensing Agreement with Janssen Sciences Ireland 242

Janssen Biotech Enters into Licensing Agreement with Ionis Pharma 242

Janssen Biotec Enters into Licensing Agreement with MacroGenics 243

Janssen Biotech Enters into Licensing agreement with Tesaro 244

Janssen Biotech Exercises Option for Licensing Agreement with X-Chem 245

ViaCyte Enters into Licensing Agreement with Janssen Biotech 246

Johnson & Johnson Innovation and Janssen Pharma Enter into Licensing Agreement with Chia Tai Tianqing Pharma 247

Janssen Biotech Exercises Option for Licensing Agreement with Scholar Rock 248

Janssen Pharma Enters into Licensing Agreement with Bavarian Nordic 249

Janssen Pharma to Enter into Licensing Agreement with Hanmi Pharma 250

Dishman Pharma Enters into Licensing Agreement with Janssen Pharma 250

Janssen Biotech to Enter into Licensing Agreement with Alligator Bioscience for ADC-1013 251

Poseida Therapeutics Enters into Licensing Agreement with Janssen Biotech 252

Arcturus Therapeutics Enters into Licensing Agreement with Janssen Pharma 253

BRIM Biotechnology Enters into Licensing Agreement with Janssen Pharma 254

Poseida Therapeutics Enters into Licensing Agreement with Janssen 255

Novo Nordisk Enters into Licensing Agreement with Janssen Biotech 256

Janssen Pharma Enters into Licensing Agreement with Achillion Pharma 256

Ichor Medical Systems Enters into Licensing Agreement with Janssen Pharma 258

Applied Molecular Transport Enters into Licensing Agreement with Janssen Biotech 259

MacroGenics Enters into Licensing Agreement with Janssen Biotech for MGD011 259

Vedanta Biosciences Enters into Licensing Agreement with Janssen Biotech 261

AC Immune Enters into Licensing Agreement with Janssen Pharma 261

Eiger BioPharma Enters into Licensing Agreement with Janssen Pharma for Tipifarnib 262

Kura Oncology Expands Licensing Agreement with Janssen Pharma 263

Addex Therapeutics Amends Licensing Agreement with Janssen Pharma 265

Halozyme Therapeutics Enters into Licensing Agreement with Janssen Biotech 266

Geron Enters into Licensing Agreement with Janssen Biotech for Imetelstat 267

Modern Biosciences Enters into Licensing Agreement with Janssen Biotech 269

Transposagen BioPharma Enters into Licensing Agreement with Janssen Biotech 270

AB-Biotics Enters into Licensing Agreement with Cilag 271

Bavarian Nordic Enters into Licensing Agreement with Crucell Holland 272

Aduro BioTech Enters into Licensing Agreement with Janssen Biotech 273

ViaCyte Enters into Option for Licensing Agreement with Janssen Research & Development 274

Minerva Enters into Licensing Agreement with Janssen Pharma for MIN-202 275

Vertex Pharma Enters into Licensing Agreement with Janssen Pharma for VX-787 276

Aduro BioTech Enters into Exclusive Licensing Agreement with Janssen Biotech 277

Johnson & Johnson Acquires Crucell 412

Johnson & Johnson - Key Competitors 415

Key Employees 416

Locations And Subsidiaries 418

Head Office 418

Other Locations & Subsidiaries 418

Recent Developments 438

Strategy And Business Planning 438

Apr 05, 2016: Johnson & Johnson Announces Launch of New Global Public Health Strategy at Opening of New Operations in Africa 438

Financial Announcements 440

Apr 19, 2017: Johnson & Johnson reports Q1 2017 results 440

Apr 18, 2017: Johnson & Johnson Reports 2017 First-Quarter Results 442

Jan 24, 2017: Johnson & Johnson Reports 2016 Fourth-Quarter Results 444

Oct 18, 2016: Johnson & Johnson Reports 2016 Third-Quarter Results 446

Jul 19, 2016: Johnson & Johnson Reports 2016 Second-Quarter Results 448

Apr 19, 2016: Johnson & Johnson Reports 2016 First-Quarter Results 450

List of Figures

Johnson & Johnson, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 21

Johnson & Johnson, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 22

Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 23

Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 24

Johnson & Johnson, Medical Devices Deals, 2011 to YTD 2017 26

List of Tables

Johnson & Johnson, Pharmaceuticals & Healthcare, Key Facts, 2017 1

Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 21

Johnson & Johnson, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 22

Johnson & Johnson, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 23

Johnson & Johnson, Deals By Therapy Area, 2011 to YTD 2017 24

Johnson & Johnson, Medical Devices Deals, 2011 to YTD 2017 26

Johnson & Johnson, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 28

Cilag Acquires Rights to Rhinocort Aqua Outside the US from Astrazeneca 59

Janssen Pharma Acquires Royalty Rights To Incivo From Vertex Pharma For US$152 Million 59

Janssen Pharma Acquires Investigational NS5A Inhibitor From Medivir 61

J.B. Chemicals Completes Sale Of Its Russian OTC Business To Cilag 62

Pulmocide Raises USD30.4 Million in Series B Financing 63

Grail Raises Funds in First Tranche of Series B Financing 64

Fusion Pharma Raises USD19 Million in Series A Financing 67

SuperX Raises USD11 Million in Series A Financing 67

Caelus Health Raises USD2.7 Million in Series A Financing 68

ApoGen Biotech Raises USD7 Million in Series A Financing 69

ReVision Optics Raises USD32 Million in Venture Financing 70

Blackthorn Therapeutics Raises USD40 Million in Series A Financing 72

V-Wave Raises USD28 Million in Venture Financing 73

Lodo Therapeutics Raises USD17 Million in Series A Financing 74

Aelix Therapeutics Raises USD12.7 Million in Series A Financing 75

Petra Pharma Raises USD48 Million in Series A Financing 76

Navitor Pharma Raises USD33 Million in Series B Financing 78

First Aid Shot Therapy Raises USD24 Million in Series C Financing 79

PrEP Biopharm Raises USD32.4 Million in Series A Financing Round 80

Asceneuron Raises USD30.6 Million in Series A Financing 81

Merus Raises USD46.4 Million in First Tranche of Series C Financing 83

Alligator Bioscience to Raise Funds through Venture Financing 84

Protagonist Therapeutics Raises USD40 Million in Series C Financing 85

PhaseBio Pharma Raises USD40 Million in Series C Venture Financing 86

Protagonist Therapeutics Raises Additional Funds through Second Tranche of Series B Venture Financing 88

La Lumiere Raises USD20 Million in Series B Venture Financing 89

Tetra Discovery Raises Funds through Venture Financing 90

XW Labs Raises USD5.5 Million in Series A Financing 90

Inivata Raises USD6.5 Million in Venture Financing 91

Inviata Raises USD6.5 Million in Venture Financing 92

ViaCyte Raises Additional USD5.4 Million in Series C-1 Venture Financing 93

Ascelegen Therapeutics Raises Funds through Venture Financing 94

Padlock Therapeutics Raises Funds through Series A Financing 95

Navitor Pharma Raises USD24 Million in Series A Financing 96

Aduro BioTech Raises USD55 Million in Series C Financing 97

Rodin Therapeutics Raises USD13 Million in Series A Venture Financing 98

Assembly Pharma Raises Funds Through Seed Financing 99

Alios BioPharma Raises US$41 Million In Series B Venture Financing 100

Covagen Raises US$50.3 Million In Series B Financing 101

Novira Therapeutics Raises US$28 Million In Series A Financing 103

SutroVax Raises Funds Through Initial Financing Round 104

TopiVert Raises USD28 Million in Venture Financing 105

TopiVert Raises US$7.4 Million In Venture Financing 106

Pulmocide Raises US$27.4 Million In Series A Financing 108

Biocartis Raises US$40.5 Million In Series E Financing 109

Merus Raises US$42 Million In Extended Series B Financing 111

Rodin Therapeutics Raises Funds Through Seed Financing 113

Vedanta Biosciences Raises Funds Through Venture Financing 113

XO1 Raises USD11 Million in Venture Financing 114

X01 Raises US$11 Million In Series A Financing 115

Catalyst Biosciences Secures USD5.07 Million in Venture Funding 116

Novira Therapeutics Secures USD25 Million in Venture Funding 117

Aquinox Pharma Raises US$18 Million In Series C Financing 118

Biocartis Raises US$44.7 Million In Series D Financing 119

Genocea Biosciences Raises US$30 Million In Series C Financing 120

Aragon Pharma Raises US$50 Million In Series D Financing 123

PhaseBio Pharma Raises Additional US$23 Million In The Third Tranche Of Series B Financing Round 124

Celladon Raises Additional US$10 Million In Series D Financing 125

Direct Flow Medical Secures USD0.28 Million in Venture Funding 127

Coherex Medical Secures USD16.5 Million in Venture Funding 128

Aragon Pharma Raises US$42 Million In Series C Financing 128

Biocartis Secures US$96 Million In Series C Financing Round 130

Novira Therapeutics Secures US$1 Million In Second Round Of Seed Financing 131

Spinal Modulation Secures US$30 Million In Series D Financing 132

23andMe Raises Additional USD9 Million in Series C Financing 134

Genocea Biosciences Secures US$35 Million In Series B Venture Financing 135

Johnson & Johnson Innovation-JJDC Invests USD4.7 Million in TRACON Pharma 137

Water Street Healthcare Partners Acquires OraPharma 138

Janssen Amends Licensing Agreement with Gilead for STR 139

Janssen Enters Into Licensing Agreement With PATH For Rilpivirine 140

Phagelux Enters into Agreement with Johnson & Johnson Consumer 141

Janssen Research & Development Enters into Agreement with Castleman Disease Collaborative Network 141

PeptiDream Enters into Agreement with Janssen Pharma 142

Janssen Pharma Enters into Partnership with Premier 143

Renova Therapeutics Enters into Agreement with Janssen Pharma 144

Mitsubishi Tanabe Pharma Enters into Co-Promotion Agreement with Janssen Pharma for Stelara 144

Janssen Research & Development Enters into Research Agreement with Weizmann Institute of Science 145

Janssen Research & Development Enters into Agreement with DayTwo and the Weizmann Institute of Science 146

Janssen Research & Development Enters into Agreement with ChemDiv 147

DePuy Synthes Enters into Co-Promotional Agreement with Pacira Pharma for EXPAREL 148

Janssen Vaccines & Prevention Enters into Research and Licensing Option Agreement with Synthetic Genomics 149

Janssen Biotech Partners with Weill Cornell Medicine to Develop Prostate Cancer Therapies 150

Janssen Pharma Enters into Partnership with Bird Rock Bio 150

Amorsa Therapeutics Enters into Partnership with Janssen Pharmaceuticals 151

Janssen Pharma and Medicines for Malaria Venture to Develop Injectable Anti-Malarial Agents 151

Karolinska Institutet Partners with Johnson & Johnson Companies 152

Janssen Biotech Enters into Partnership with Bristol-Myers 153

Janssen Biotech Enters into Clinical Trial Agreement with Onyx Pharma 154

HitGen Enters into Agreement with Janssen Biotech 154

Innovative Targeting Solutions Enters into Research Agreement with Janssen Biotech 155

Xycrobe Therapeutics Enters into Research Agreement with Johnson & Johnson Consumer 156

Philogen Enters into Co-Development Agreement with Janssen Biotech 156

Diamyd Medical Enter into Partnership with Janssen R&D, JDRF and UAB 157

Bristol-Myers Squibb Enters into Research Agreement with Janssen Biotech 158

Amyris Enters into Research Agreement with Janssen Biotech 159

Janssen Research & Development Enters into Agreement with Genentech 160

Mitsubishi Tanabe Pharma Enters into Distribution Agreement with Janssen Biotech 161

DiamiR Enters into Research Agreement with Janssen Pharma 161

Janssen Biotech Enters into Research Agreement with David H. Koch Institute for Integrative Cancer 162

Janssen Biotech Enters into Agreement with HUB foundation 163

Janssen Pharma Enters into Agreement with University of Pennsylvania 163

Janssen Pharma Enters into Agreement with University of Wisconsin-Madison 164

Johnson & Johnson Consumer Enters into Agreement with ProdermIQ 165

Johnson & Johnson Consumer Enters into Research Agreement with University of Pennsylvania 165

Janssen Biotech Enters into Research Agreement with David H. Koch Institute for Integrative Cancer 166

ViiV Healthcare Enters into Agreement with Janssen Sciences Ireland UC 167

Janssen Pharma Enters into Agreement with University of California, San Diego 167

Enterome Bioscience Enters into Research Agreement with Janssen Biotech 168

Johnson & Johnson Consumer Enters into Agreement with BioMed X 169

Janssen Pharma Enters into Research Agreement with Institute for Systems Biology 169

Janssen Research & Development Enters into Research Agreement with Skaggs School of Pharmacy and Pharmaceutical Sciences 170

Janssen Biotech Enters into Agreement with Eureka Therapeutics 171

Intrexon Enters into Research Agreement with Janssen Pharma 171

Cypralis Enters into Research Agreement with Janssen Pharma 172

Janssen Pharma Enters into Agreement with Foundation for Innovative New Diagnostics 173

Bioaster, Cancer Research Center of Lyon and Janssen-Cilag Enter into Agreement 174

Nuevolution Enters into Discovery Agreement with Janssen Biotech 174

enGene Enters into Agreement with Janssen Biotech 175

OICR and Novera Therapeutics Enter into Co-Development Agreement with Janssen Biotech 176

BlinkBio Enters into Discovery Agreement with Janssen Pharma 177

UbiVac Enters into Agreement with Janssen Biotech 177

Protectimmun Enters into Research Agreement with Janssen Biotech And Imperial College 178

Nextera Enters into Research Agreement with Janssen Biotech 179

Johnson & Johnson Innovation Enters into Research Agreement with Washington University 180

Janssen Biotech Enters into Research Agreement with Emulate 180

Johnson & Johnson Innovation Partners with Lead Discovery Center 181

Johnson & Johnson Enters into Agreement with University of the Witwatersrand 182

Janssen Cilag Enters into Agreement with UniQuest 182

AC Immune Enters into Research Agreement with Janssen Pharma 183

X-Chem Expands Agreement with Janssen Biotech 184

Vectura Enters into Development and License Agreement with Janssen Biotech 184

Isis Pharma Enters into Agreement with Janssen Biotech to Discover and Develop RNA-Targeted Therapeutics 185

Sevion Therapeutics Enters into Discovery Agreement with CNA Development 186

Atreca Enters into Research Agreement with Janssen Biotech 187

Vaccinex Enters into Research Agreement with Janssen Research & Development 188

Mitsubishi Tanabe Enters into Co-Promotion Agreement with Johnson & Johnson K.K. 188

Weill Cornell Medical College Enters into Co-Development Agreement with Janssen Biotech and Johnson & Johnson Innovation 189

Johnson & Johnson Enters into Co-Development Agreement with University of Manchester 190

ViiV Healthcare Enters into Co-Development Agreement with Janssen R&D Ireland 191

Alector Enters Into Research Agreement With Janssen Pharma 192

Jubilant Biosys Extends Drug Discovery Agreement With Janssen Pharma 192

University of Texas MD Anderson Cancer Center Enters Into Co-Development Agreement With Johnson & Johnson Innovation And Janssen Biotech 193

Nodality Enters Into Research Agreement With Johnson & Johnson Innovation 195

Scholar Rock Enters Into Research Collaboration With Johnson & Johnson Innovation And Janssen Biotech 195

Intrexon Enters Into R&D Agreement With Johnson & Johnson Innovation For Skin And Hair Products 197

Capricor Enters Into Co-Development Agreement With Janssen For Cell Therapy For Cardiovascular Applications 197

Evotec Enters Into Co-Development Agreement With Johnson & Johnson 198

AstraZeneca Enters Into Co-Promotion Agreement With Janssen For Abiraterone Acetate 199

Joslin Diabetes Center Enters Into R&D Agreement With Johnson & Johnson For Diabetes Management 200

Open Monoclonal Expands Agreement with CNA Development 201

DCPrime And Janssen Pharma Enter Into Research Agreement For Cell-Based Vaccine 202

Katholieke Universiteit Leuven And Wellcome Trust Enter Into Agreement With Janssen Pharma To Develop Dengue Antiviral Drugs 202

ex scientia Enters into Agreement with Janssen Research & Development 204

Mellitech Enters into Agreement with Janssen Pharma 204

Second Genome Enters Into Agreement With Janssen Biotech For Microbiome Drug Discovery 205

Janssen Biotech Enters Into Agreement With CRT And ICR To Discover Multiple Myeloma Drug 206

Araxes Pharma Enters Into Drug Discovery Agreement With Janssen Biotech For Cancer 207

Idenix Pharma Enters Into Co-Development Agreement With Janssen Pharma 208

Open Monoclonal Technology Enters Into Agreement With CNA Development For OmniRat Antibody 209

Beactica Enters Into Research Agreement With Janssen Research & Development 209

Janssen-Cilag Enters Into Research Agreement With University of Melbourne 210

Takeda Pharma Enters Into Distribution Agreement With Johnson & Johnson For Seven OTC Brands 211

Artes Biotechnology Enters Into Co-Development Agreement With Crucell 212

Selventa Enters Into Co-Development Agreement With Janssen Research & Development 212

Johnson & Johnson Enters Into Co-Development Agreement With University of Queensland 213

Dendright Enters Into Research Agreement With Janssen-Cilag 214

FORMA Therapeutics Enters Into Co-Development Agreement With Janssen Biotech 215

ChemDiv Enters Into Research Agreement With Janssen Pharmaceutica And Tibotec Pharma 216

Molecular Partners Enters Into Research Agreement With Janssen Biotech 216

Topivert Enters into Drug Discovery Collaboration Agreement with RespiVert 217

Skyline Diagnostics Enters Into Research Collaboration With Johnson & Johnson Pharma 218

Jubilant Enters Into Drug Discovery Agreement With Janssen Pharmaceutica 219

ChemRar High Tech Center Enters Into Co-Development Agreement With Janssen Pharma 220

Synthes Enters Into Co-Development Agreement With Eli Lilly 220

PATH Malaria Vaccine Initiative Enters Into An Agreement With Crucell And GlaxoSmithKline 221

NeuroSearch Extends Research Agreement With Janssen Pharmaceutica 223

Beactica Enters Into An Agreement With Janssen 223

Merck Amends Distribution Agreement With Johnson & Johnson 224

Medivir Enters Into Collaboration With Janssen Pharmaceutica 225

Johns Hopkins Brain Science Institute Enters Into An Agreement With Ortho-McNeil-Janssen 226

Sanford-Burnham Medical Enters Into Collaboration With Ortho-McNeil-Janssen Pharma 227

Veridex Enters Into Co-Development Agreement With Massachusetts General Hospital 228

Stereotaxis Amends Co-Development Agreement With Biosense Webster 229

Janssen Pharma Enters into Licensing Agreement with Medivir 230

Janssen Biotech Enters into Licensing Agreement with Trianni 231

Janssen Biotech Enters into Licensing Agreement with Ablexis 232

Akebia Therapeutics Enters into Licensing Agreement with Janssen Pharma 232

Janssen Pharma Enters into Licensing Agreement with University of Massachusetts 233

CPDC Enters into Licensing Agreement with Janssen Biotech for Centyrin 234

OCTIMET Oncology Enters into Licensing Agreement with Janssen Pharma 235

Janssen Expands Licensing Agreement with Gilead 235

BenevolentAI Enters into Licensing Agreement with Janssen Pharma 237

SuperGen Completes Acquisition Of Astex Therapeutics 409

Johnson & Johnson Acquires Crucell 412

Johnson & Johnson, Key Competitors 415

Johnson & Johnson, Key Employees 416

Johnson & Johnson, Subsidiaries 418

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Johnson & Johnson, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16263
Site License
USD 500 INR 32525
Corporate User License
USD 750 INR 48788

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com